Clinical Trial Detail

NCT ID NCT02359851
Title Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

uveal melanoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.